A phase I clinical study of adoptive transfer of regulatory T cells (Tregs) and low-dose interleukin-2 (IL-2) for the treatment of chronic graft-versus-host disease (GVHD): gene-marking to inform rational combination therapy

调节性 T 细胞 (Treg) 和低剂量白细胞介素 2 (IL-2) 过继转移治疗慢性移植物抗宿主病 (GVHD) 的 I 期临床研究：基因标记为合理的联合治疗提供信息

• 批准号: nhmrc : GNT1163111
• 金额: $ 87.87万
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2019
• 资助国家: 澳大利亚
• 起止时间: 2019-01-01 至 无数据
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/phase-i-clinical-combination-therapy/1379275
• 关键词: phase; clinical; study; adoptive; transfer

Bone marrow transplantation can cure leukaemia but is often complicated by graft-versus-host disease (GVHD), which greatly reduces quality- of-life. A type of immune cell, called regulatory T cells (Tregs), may help. We will expand donor Tregs in the laboratory and infuse them into patients with chronic GVHD. We will gene-mark the cells so that we can understand what happens after infusion. We will also investigate whether interleukin-2 given at the same time can make the Tregs more effective.

骨髓移植可以治愈白血病，但往往并发移植物抗宿主病（GVHD），这大大降低了生活质量。一种称为调节性T细胞（Tcells）的免疫细胞可能会有所帮助。我们将在实验室扩大供体TdR，并将其注入慢性GVHD患者。我们将对细胞进行基因标记，以便我们能够了解输注后会发生什么。我们还将研究同时给予白细胞介素-2是否能使THBE更有效。